Journal of Pharmacology and Pharmacotherapeutics

REVIEW ARTICLE
Year
: 2015  |  Volume : 6  |  Issue : 2  |  Page : 71--76

Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis


Marianne Frieri1, William Heuser2, Joshua Bliss2 
1 Department of Medicine, Nassau University Medical Center, St Johns University, New York, USA
2 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St Johns University, New York, USA

Correspondence Address:
William Heuser
College of Pharmacy and Health Sciences, St. John«SQ»s University, 8000 Utopia PkwyQueens, NY 11439
USA

Recently introduced into the market, belimumab (Benlysta) is a monoclonal antibody that has potential clinically efficacious applications for the treatment of lupus nephritis. Lupus nephritis is a major complication of systemic lupus erythematosus (SLE) that can lead to significant illness or even death without proper intervention and treatment. With vast implications through a novel mechanism, belimumab offers a new standard of treatment for physicians in the complications associated with SLE, specifically lupus nephritis. By targeting B cell signaling and maturation, belimumab is able to mitigate the underlying pathological complications surrounding SLE. Phase 3 clinical trials with belimumab have depicted clinically efficacious applications, suggesting belimumab as a revolutionary breakthrough in the treatment armamentarium for practicing clinicians. This article explains the precise mechanism of action of belimumab on the soluble protein BlyS that plays a major role in the pathogenesis of lupus nephritis. In addition, the extensive pharmacokinetics and clinical implications are exemplified in this review with belimumab«SQ»s comparison with standard therapeutic guidelines for the treatment of lupus nephritis.


How to cite this article:
Frieri M, Heuser W, Bliss J. Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis.J Pharmacol Pharmacother 2015;6:71-76


How to cite this URL:
Frieri M, Heuser W, Bliss J. Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis. J Pharmacol Pharmacother [serial online] 2015 [cited 2022 Jan 19 ];6:71-76
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2015;volume=6;issue=2;spage=71;epage=76;aulast=Frieri;type=0